SCHEMBL5208935

SCHEMBL5208935

COc1ccc2[nH]c(C)c(CC(=O)Nc3cc(Cl)ccc3C(=O)O)c2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.62
▸ KMT2A Q03164 5/20 0.62
▸ MAPT P10636 2/20 0.62
▸ AKR1C2 P52895 2/20 0.59
▸ POLB P06746 1/20 0.54
▸ HDAC1 Q13547 6/20 0.53
▸ HDAC3 O15379 1/20 0.52
▸ HDAC4 P56524 1/20 0.52
▸ HDAC2 Q92769 1/20 0.52
▸ HDAC6 Q9UBN7 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ GRIK1 P39086 2/20 0.51
▸ MTNR1A P48039 1/20 0.49
▸ MTNR1B P49286 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ PTPN5 P54829 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5209948 0.92 MAPT (0.62) MEN1KMT2AMAPTAKR1C2POLB
SCHEMBL5214528 0.90 AKR1C2 (0.61) MEN1KMT2AMAPTAKR1C2POLB
SCHEMBL5208570 0.88 AKR1C2 (0.59) MEN1KMT2AMAPTAKR1C2POLB
SCHEMBL5209238 0.88 AKR1C2 (0.59) MEN1KMT2AMAPTAKR1C2POLB
SCHEMBL5211125 0.87 AKR1C2 (0.58) MEN1KMT2AMAPTAKR1C2POLB
SCHEMBL5206552 0.87 AKR1C2 (0.63) MEN1KMT2AMAPTAKR1C2POLB
SCHEMBL5210674 0.86 MAPT (0.54) MEN1KMT2AMAPTPOLBKDM4E
SCHEMBL5211075 0.86 AKR1C2 (0.56) MEN1KMT2AMAPTAKR1C2POLB
SCHEMBL5210270 0.85 AKR1C2 (0.60) MEN1KMT2AMAPTAKR1C2POLB
SCHEMBL5207378 0.85 AKR1C2 (0.55) MEN1KMT2AMAPTAKR1C2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 — — US claimed
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 — — US disclosed
EP-1343757-B1 INDOLE DERIVATIVES GLAXO GROUP LTD (GB) 2007-02-14 — — EP disclosed
US-20040092569-A1 Indole derivatives GLAXO GROUP LIMITED (GB) 2004-05-13 — — US disclosed
EP-1343757-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-09-17 — — EP disclosed
WO-2002050031-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2002-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092569-A1 Indole derivatives PTGER4, PTGER1, TRPV4 MEN1 2074/4885KMT2A 3855/4885MAPT 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback